Month: October 2013

New Findings from Texas Tech University School of Medicine in the Area of Immunotherapy Described

Data detailed on Biotechnology have been presented. According to news reporting from Lubbock, Texas, by NewsRx journalists, research stated, “Neuroblastoma (NB) is the most common extracranial solid tumor in children. Combining passive immunotherapy with an antibody to the disialoganglioside GD2 (ch14.18/SP2/0) and cytokines with 13-cis-retinoic acid for post-myeloablative maintenance therapy increased survival in high-risk NB, but the overall prognosis for these children […]

read more